Physician profile
Maaz Ahmed
NPI 1336165133
$3,952.91
in general payments reported to CMS, 2019-2025
24 companies · $800 in 2025
The $800 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $447 · 2021: $563 · 2022: $729 · 2023: $486 · 2024: $448 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $802.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.34 | 2019-2025 | Jardiance, Jascayd |
| Abbvie INC. | $408.33 | 2019-2025 | Linzess, Viberzi, Vraylar |
| Glaxosmithkline, LLC. | $386.74 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $310.31 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $216.17 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $207.56 | 2019-2025 | |
| Corcept Therapeutics | $194.01 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $173.78 | 2019-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $126.37 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.34 | 2021-2025 | |
| Exact Sciences Corporation | $96.32 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $80.49 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $78.16 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $75.62 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $54.28 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $41.30 | 2023-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.06 | 2020-2023 | Xifaxan |
| Amarin Pharma, INC. | $28.78 | 2020 | |
| Tonix Medicines, INC. | $23.27 | 2025 | Tonmya |
| Boston Scientific Corporation | $19.04 | 2025 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $18.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.58 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maaz Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.